Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Post Bariatricsurgery, Hypoglycemia
Interventions
Exendin-(9-39), Atropine, GLP-1 and GIP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144
Conditions
Monogenic Diabetes
Interventions
GLP-1, Exendin 9-39
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907
Conditions
Insulin Secretion
Interventions
Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Results available

Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930
Conditions
Obesity, PreDiabetes
Interventions
Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin 9, 39, Placebo
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

NCT02170870
Conditions
Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions
Exendin 9-39, Microlipid, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Bariatric Surgeries on Glucose Metabolism

NCT02823665
Conditions
Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Hypoglycemia After Gastric Bypass
Interventions
Exendin-(9-39), Atropine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

NCT06967558
Conditions
PreDiabetes
Interventions
Exendin 9-39, Saline
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Conditions
Post-bariatric Hypoglycemia
Interventions
Avexitide
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Boston, Massachusetts • Morehead City, North Carolina • Mesquite, Texas + 1 more
Terminated Phase 1 Interventional Accepts healthy volunteers

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

NCT02550145
Conditions
Hypoglycemia
Interventions
Exendin (9-39), Placebo
Drug · Other
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Not listed Not applicable Interventional Accepts healthy volunteers

Ghrelin Effect on Beta Cell Function in Health and Disease

NCT01729299
Conditions
Diabetes
Interventions
Exendin (9-39), acyl ghrelin, saline
Drug
Lead sponsor
David Dalessio
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Post Bariatric Hypoglycemia
Interventions
Lyo avexitide, Liq avexitide
Drug
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Hyperinsulinemia Hypoglycemia
Interventions
Exendin (9-39)
Drug
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Role of GLP-1 in Satiety Perception in Humans

NCT01152333
Conditions
Appetite Regulation, Obesity
Interventions
Exendin-(9-39) Acetate, Saline 0.9%
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Seattle, Washington